1. Modern treatment outcomes for early T-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution
- Author
-
Adrian Mendez, John W. Barrett, Eric Winquist, Nancy Read, Lucas C. Mendez, Tricia Chinnery, Varagur Venkatesan, Kevin Fung, Anthony C. Nichols, Eric Di Gravio, Hugh Andrew Jinwook Kim, Sylvia Mitchell, Sarah A. Mattonen, Neil Mundi, David A. Palma, Sara Kuruvilla, S. Danielle MacNeil, Joe S. Mymryk, Pencilla Lang, and John Yoo
- Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine ,Male ,medicine.medical_specialty ,lcsh:R895-920 ,medicine.medical_treatment ,Neutropenia ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Transoral robotic surgery ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Stage (cooking) ,Feeding tube ,Aged ,Neoplasm Staging ,Retrospective Studies ,Oropharyngeal cancer ,Radiation ,Toxicity ,business.industry ,Squamous Cell Carcinoma of Head and Neck ,Tertiary Healthcare ,Research ,Cancer ,Common Terminology Criteria for Adverse Events ,Chemoradiotherapy, Adjuvant ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Dysphagia ,3. Good health ,Radiation therapy ,Oropharyngeal Neoplasms ,Oncology ,Chemoradiation ,030220 oncology & carcinogenesis ,Female ,Radiotherapy, Intensity-Modulated ,medicine.symptom ,business - Abstract
Background Transoral surgery (TOS), particularly transoral robotic surgery (TORS) has become the preferred modality in the United States for the treatment of early stage oropharyngeal cancer, largely due to assumptions of fewer toxicities and improved quality of life compared to primary radiotherapy (RT). However, these assumptions are based on retrospective analysis, a subset of which utilize primary RT groups not limited to T1-2 stage tumors for which transoral robotic surgery is FDA approved. Thus, there is potential for underestimating survival and overestimating toxicity, including treatment related mortality, in primary RT. Methods Consecutive cases of early T-stage (T1–T2) oropharyngeal cancer presenting to the London Health Sciences Centre between 2014 and 2018 treated with RT or chemoradiation (CRT) were reviewed. Patient demographics, treatment details, survival outcomes and toxicity were collected. Toxicities were retrospectively graded using the Common Terminology Criteria for Adverse Events criteria. Results A total of 198 patients were identified, of which 82% were male and 73% were HPV-positive. Sixty-eight percent of patients experienced a grade 2 toxicity, 48% a grade 3 and 4% a grade 4. The most frequent toxicities were dysphagia, neutropenia and ototoxicity. The rates of gastrostomy tube dependence at 1 and 2 years were 2.5% and 1% respectively. There were no grade 5 (fatal) toxicities. HPV-positive patients experienced improved 5-year overall survival (86% vs 64%, p = 0.0026). Conclusions Primary RT or CRT provides outstanding survival for early T-stage disease, with low rates of severe toxicity and feeding tube dependence. This study provides a reference for comparison for patients treated with primary transoral surgery.
- Published
- 2020